Subscribe To
Audusd weekly analysis – july 15, 2023
The AUDUSD pair has been engaged in a sideways movement, oscillating within the range of 0.6170 and 0.7157. This consolidation ...
July 15, 2023, 3:48 am
Cara therapeutics faces uncertainty despite potential reimbursement extension for korsuva
Cara Therapeutics' Korsuva injection, approved for treating pruritus in adults with chronic kidney disease, may have its reimbursement period extended...
July 14, 2023, 5:11 pm
Gbp/usd shifts the focus to 1.3335 – uob
GBP/USD is recovering ground above 1.3100, entering a consolidative phase in the European session. The ...
July 14, 2023, 12:44 pm
Usdjpy daily analysis – july 14, 2023
The USDJPY currency pair has entered a consolidation phase after finding support at 137.23, following a...
July 14, 2023, 12:26 pm
Qqqe and xle: balanced etf strategy for the next phase of this bull market
I suggest a trade strategy using the equal-weighted Nasdaq ETF and Energy ETF, which complement each other's weaknesses and could lead to outperforman...
July 14, 2023, 11:21 am
Enphase (enph) unveils iq batteries in spain and portugal
Enphase (ENPH) recently unveiled IQ Batteries for the solar markets of Spain and Portugal....
July 14, 2023, 11:09 am
Why is theseus pharmaceuticals (thrx) stock down 68% today?
Theseus Pharmaceuticals (NASDAQ: THRX ) stock is falling hard on Friday after the company announced poor results from a ...
July 14, 2023, 8:46 am
3 stocks to buy for artificial intelligence (ai) exposure
While artificial intelligence (AI) is still in its early phases, the long-term potential has investors ecstatic, seeing a massive opportunity to reap ...
July 13, 2023, 7:22 pm
Ocrevus challenges briumvi: a closer look at tg therapeutics' position
TG Therapeutics, Inc.'s Briumvi, a treatment for multiple sclerosis, faces competition from Roche's Ocrevus, which has shown positive results in a
July 13, 2023, 5:49 pm
Daré bioscience's 'female viagra' could be first-in-category product: broker
Daré Bioscience could have a first-in-category product on its hands with its “female Viagra” offering, analysts at Dawson James believe. The wome...
July 13, 2023, 4:26 pm
Viridian: despite drop, advancement towards phase 3 continues
There were positive results achieved from Viridian Therapeutics, Inc. phase 1/2 study using VRDN-001 fo...
July 13, 2023, 3:16 pm
Nextdecade shares fall 23% as lng project funding disappoints investors
NextDecade Corp shares fell 23% on Thursday on investor worries over the terms of $18.4 billion financing the U.S. liquefied natural gas developer obt...
July 13, 2023, 1:07 pm
Domino's pizza: fairly valued amid new growth plans
Domino's Pizza Inc. ( DPZ , Financial) saw its stock price surge 11% higher on July 12 after announcing a global delivery partnership with Uber's ( UB...
July 13, 2023, 11:25 am
Euo: in the event that the euro project enters terminal phase
I discuss potential investment opportunities in Short ETFs, particularly betting against the euro currency. The euro is likely to see a severe downtur...
July 13, 2023, 12:39 am
Seelos: 2 catalysts before end of 2023 make this a must watch
Results from Part 2 of the phase 2 registration-directed study, using SLS-002 for acute suicidal ideati...
July 12, 2023, 7:09 pm
Comcast (cmcsa) boosts xfinity network expansion in oregon
Comcast (CMCSA) announces the conclusion of the first phase of network expansion to homes and businesse...
July 12, 2023, 2:04 pm
Incyte's (incy) opzelura meets goal in phase iii pediatric study
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in childre...
July 12, 2023, 12:34 pm
Enphase energy announces conference call to review second quarter 2023 financial results thursday, july 27, 2023 at 4:30 p.m. eastern time
FREMONT, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Enphase Energy, Inc . (NASDAQ: ENPH), a global energ...
July 12, 2023, 8:00 am
Royal mail's pay deal fails to deliver upbeat consensus with broker
“Things will get worse before they get better” at Royal Mail after its owner, International Distributions Services struck a deal with the Communic...
July 12, 2023, 7:06 am
Aclaris therapeutics: q4 of 2023 catalyst makes this a must watch
Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patien...
July 11, 2023, 7:31 pm